Match Document Document Title
9034826 Use of epidermal growth factor for the morphofunctional restoration of peripheral nerves in diabetic neuropathy  
The present invention is relevant to human medicine, and, in particular, to the use of Epidermal Growth Factor (EGF) in a pharmaceutical composition, said composition is administered through...
9029323 Neurturin conjugates for pharmaceutical use  
The present invention relates to neurturin protein products conjugated to polyols and to pharmaceutical compositions comprising neurturin conjugates as active ingredients, preferably PEGylated...
9029330 Methods of treating cancer using interleukin-12p40 variants having improved stability  
Modified interleukin-12 (IL-12) p40 polypeptides are disclosed. The modified polypeptides have alterations in the IL-12p40 subunit to eliminate the protease site between positions Lys260 and...
9029328 Methods for cardioprotection and cardioregeneration with dimers of EGF family ligands  
The invention provides methods and compositions for reducing, preventing or reversing cardio toxicity side effects associated with certain therapeutic agents. The invention also provides methods...
9023791 Fibroblast growth factor 21 mutations  
The present invention provides novel polypeptide and protein variants of fibroblast growth factor 21 (FGF21) and pharmaceutical compositions comprising FGF21 polypeptide and protein variants.
9018357 Anti-VEGF antibodies  
Anti-VEGF antibodies and variants thereof, including those having high affinity for binding to VEGF, are disclosed. Also provided are methods of using phage display technology with naïve libraries...
9018165 Process for the synchronization of ovulation for timed breeding without heat detection  
A method for synchronizing ovulation in sows and gilts without heat detection by a single injection of hormones is disclosed. A hormone, gonadotropin releasing hormone (GnRH), luteinizing hormone...
9006400 Fibroblast growth factor-21-Fc fusion proteins  
The invention relates to the identification of fusion proteins comprising polypeptide and protein variants of fibroblast growth factor 21 (FGF21) with improved pharmaceutical properties. Also...
8992965 Bone matrix compositions and methods  
An osteoinductive composition, corresponding osteoimplants, and methods for making the osteoinductive composition are disclosed. The osteoinductive composition comprises osteoinductive factors,...
8993733 Procedure for obtaining a composition containing growth factors from a blood compound, and composition obtained by said procedure  
Procedure for obtaining a composition that contains growth factors, which comprises the steps of heat-treating a platelet-rich plasma or the supernatant of a platelet-rich plasma that contains...
8980249 Agonists of growth hormone releasing hormone as effectors for survival and proliferation of pancreatic islets  
Agonists of growth hormone releasing hormone promote islet graft growth and proliferation in patients. Methods of treating patients comprise the use of these agonists.
8969042 Refolding transforming growth factor beta family proteins  
Compositions and methods for folding proteins belonging to the transforming growth factor beta superfamily are disclosed. The compositions and methods allow for the folding of such proteins when...
8962556 FGF-2 variants having N-terminal deletions and increased receptor selectivity and uses thereof  
The present invention relates to the design, manufacture and use of fibroblast growth factor (FGF) polypeptides having improved receptor specificity. In particular, the invention relates to...
8962813 Purification and use of a factor for supporting wound healing  
A process for manufacturing of a composition containing a purified factor for supporting wound healing selected from the group consisting of Hepatocyte Growth Factor (HGF) platelet derived growth...
8962555 PlGF-1 in homodimeric form  
The present invention relates to a new homodimeric form of recombinant PlGF-1, to a process for its preparation and to compositions containing it.
8957021 Glucose-regulating polypeptides and methods of making and using same  
The present invention relates to compositions comprising glucose regulating peptides linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors...
8951966 Compositions comprising variants and fusions of FGF19 polypeptides, and uses and methods thereof for treatment of metabolic disorders and diseases  
The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of fibroblast growth factor 19 (FGF19)...
8946155 Long-acting polypeptides and methods of producing and administering same  
A polypeptide and polynucleotides comprising at least two carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to a non-human peptide-of-interest are disclosed. Pharmaceutical...
8940305 Formulation of human antibodies for treating TNF-α associated disorders  
A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
8937044 Process for the synchronization of ovulation for timed breeding without heat detection  
A method, for synchronizing ovulation in sows and gilts by a single injection of hormones is disclosed. A hormone, gonadotropin releasing hormone (GnRH), luteinizing hormone (LH), follicle...
8937043 Method for obtaining a TGF-beta enriched protein fraction in activated form, protein fraction and therapeutic applications  
The invention concerns a method for obtaining a highly enriched TGF-beta protein fraction in activated form, from a liquid solution rich in proteins said to be soluble in the aqueous phase of milk...
8933034 Chimeric neuregulins and method of making and use thereof  
Composition containing a chimeric neuregulin polypeptides and method of making such polypeptides are disclosed. The chimeric neuregulin comprises a first moiety of at least 10 amino acids, wherein...
8932591 Formulation of human antibodies for treating TNF-α associated disorders  
A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
8933197 Compositions comprising modified biologically active polypeptides  
The present invention relates to biologically active polypeptides linked to one or more accessory polypeptides. The present invention also provides recombinant polypeptides including vectors...
8932828 Method for preparing recombinant granulocyte colony stimulating factor cysteine muteins  
The present invention relates to novel methods for making and refolding insoluble or aggregated proteins having free cysteines in which a host cell expressing the protein is exposed to a cysteine...
8927492 Fibroblast growth factor 21 proteins  
This present invention relates to pharmacologically potent and stable human fibroblast growth factor 21 (FGF21) proteins, pharmaceutical compositions comprising FGF21 proteins, and methods for...
8927493 Promoter for regeneration of tendon-bone junction tissue or ligament-bone junction tissue  
An object of the present invention is to provide a drug for promoting the regeneration of tendon-bone junction tissue or ligament-bone junction tissue. The present invention relates to a promoter...
8927485 Site-specific modification of proteins through chemical modification enabling protein conjugates, protein dimer formation, and stapled peptides  
The present invention generally provides methods for the site-specific modification of peptides, polypeptides, and proteins, e.g., granulocyte macrophage colony-stimulating factor, human...
8927496 Process for the synchronization of ovulation for timed breeding without heat detection  
A method for synchronizing ovulation in sows and gilts by a single injection of hormones is disclosed. A hormone, gonadotropin releasing hormone (GnRH), luteinizing hormone (LH), follicle...
8916157 Formulation of human antibodies for treating TNF-α associated disorders  
A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
8916522 FGF-9 variants and methods of use thereof  
A method of treating an individual (i) having abnormal bone; or (ii) afflicted with a disease or disorder related to normal or abnormal FGF receptors or a skeletal disorder; or (iii) having...
8916158 Formulation of human antibodies for treating TNF-α associated disorders  
A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
8911741 Formulation of human antibodies for treating TNF-alpha associated disorders  
A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
8907064 Modified human four helical bundle polypeptides and their uses  
Modified human four helical bundle (4HB) polypeptides and uses thereof are provided.
8900593 Glucagon/GLP-1 receptor co-agonists  
Modified glucagon peptides are disclosed having enhanced potency at the glucagon receptor relative to native glucagon. Further modification of the glucagon peptides by forming lactam bridges or...
8901081 Uses of GRS proteins or fragments thereof  
The present invention is related to a anticancer composition comprising full length GRS protein or a fragment thereof, a nucleic acid encoding the GRS protein or a fragment thereof. Since the GRS...
8889426 Methods of identifying inhibitors of FGF23 binding to the binary FGFR-klotho complex for the treatment of hypophosphatemia  
The present invention is directed to a method of treating hypophosphatemia in a subject. The present invention is also directed to a method of screening for compounds suitable for treatment of...
8889131 NOTCH inhibition in the treatment and prevention of a metabolic disease or disorder and cardiovascular complications thereof  
The present invention is directed to methods of treating or preventing a metabolic disease or disorder and cardiovascular complications and other complications thereof by administering agents that...
8883726 Fibroblast growth factor 21 variants  
This present invention relates to pharmacologically potent and/or stable variants of human fibroblast growth factor 21 (FGF21), pharmaceutical compositions comprising FGF21 variants, and methods...
8871915 Peptides targeting TNF family receptors and antagonizing TNF action, compositions, methods and uses thereof  
The present invention provides modulators of TNF, particularly peptides and their derivatives, particularly GEP peptides, which antagonize TNF and TNF-mediated responses, activity or signaling....
8871721 Methods for inhibiting peritoneal dissemination of cancer cells  
A pharmaceutical composition for treating or preventing peritoneal dissemination is provided. The pharmaceutical composition includes an effective dose of connective tissue growth factor (CTGF)...
8865647 Pharmaceutical solution of non covalently bound albumin and acylated insulin  
If albumin is added to a pharmaceutical formulation containing acylated insulin described in WO 2009/022005 and WO 2009/022013, the acylated insulin can be kept in solution after subcutaneous...
8865864 Mutant epidermal growth factor polypeptides with improved biological activity and methods of their making and use  
Compositions that are EGF polypeptides that possess improved biological activity as compared to the biological activity exhibited by wild-type EGF are provided. Also provided are methods for the...
8865658 Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides  
Disclosed herein are non-natural amino acids and polypeptides that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The...
8865122 Methods and compositions for protein labelling  
A modular platform is provided for rapid preparation of various water-soluble prosthetic groups capable to efficiently introduce 18F into proteins with 18F labelling reagents.
8865673 Monitoring and modulating HGF/HGFR activity  
Provided are methods and compositions for the modulation of hepatocyte growth factor activity to regulate lymphatic vessel development and function. Methods and composition for the monitoring and...
8859724 Manufacture and use of modified polysaccharide chitosan bonds and a process to improve the preparation of HES-medicinal substance compounds  
The invention relates to a bonding product suitable as a carrier for medicinal substances and to the compound derived therefrom that carries medicinal substances. The invention further relates to...
8859498 Targeted therapeutic proteins  
Targeted therapeutics that localize to a specific subcellular compartment such as the lysosome are provided. The targeted therapeutics include a therapeutic agent and a targeting moiety that binds...
8853370 Plant-produced glycoprotein comprising human-type sugar chain  
The present invention provides a method for manufacturing a glycoprotein having a human-type sugar chain comprising a step in which transformed plant cell is obtained by introducing to a plant...
8853166 Neurotrophic factor MANF and uses thereof  
The present invention generally relates to the field of treatment of neuronal disorders and more particularly to neurotrophic factor MANF and uses thereof. The present invention provides a...